Medicenna Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Medicenna Therapeutics şirketinin kazançları yıllık ortalama -14.5% oranında azalırken, Biotechs sektörünün kazançları yıllık 24.8% oranında arttı.

Anahtar bilgiler

-14.5%

Kazanç büyüme oranı

0.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	51.1%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-133.1%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Gelir ve Gider Dağılımı

Medicenna Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TSX:MDNA Gelir, gider ve kazançlar (CAD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	-27	7	11
30 Jun 24	-26	7	11
31 Mar 24	-25	8	11
31 Dec 23	-15	6	11
30 Sep 23	-12	7	10
30 Jun 23	-9	7	10
31 Mar 23	-10	7	9
31 Dec 22	-9	8	9
30 Sep 22	-13	8	9
30 Jun 22	-20	8	13
31 Mar 22	-23	8	15
31 Dec 21	-25	8	17
30 Sep 21	-26	8	17
30 Jun 21	-21	8	13
31 Mar 21	-17	7	11
31 Dec 20	-14	5	9
30 Sep 20	-11	4	8
30 Jun 20	-9	3	7
31 Mar 20	-8	2	6
31 Dec 19	-7	2	4
30 Sep 19	-6	2	4
30 Jun 19	-5	2	3
31 Mar 19	-5	2	3
31 Dec 18	-5	2	3
30 Sep 18	-5	2	3
30 Jun 18	-6	2	4
31 Mar 18	-7	2	5
31 Dec 17	-11	2	6
30 Sep 17	-11	2	7
30 Jun 17	-10	2	6
31 Mar 17	-8	2	4
31 Dec 16	-3	1	2
30 Sep 16	-2	1	1
30 Jun 16	-1	1	1
31 Mar 16	-1	0	1
31 Mar 15	-1	0	1

Kaliteli Kazançlar: MDNA şu anda kârlı değil.

Büyüyen Kar Marjı: MDNA şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MDNA kârlı değildir ve zararlar son 5 yılda yılda 14.5% oranında artmıştır.

Büyüme Hızlandırma: MDNA 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: MDNA kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 20% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: MDNA hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -133.06% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/30 06:19
Gün Sonu Hisse Fiyatı	2025/01/30 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Medicenna Therapeutics Corp. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Charles Zhu	Guggenheim Securities, LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.
Catherine Novack	JonesTrading Institutional Services, LLC

Medicenna Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022

Recent updates

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium

Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Medicenna Therapeutics Corp. Announces Management Changes

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022

Medicenna Therapeutics Corp. Announces Board Appointments

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study